Harman Finochem undertakes custom manufacturing of APIs and advanced Intermediates by offering the pharmaceutical industry a new approach for outsourcing services with a dedicated focus on enhancing value and competitive advantage to its customers over the entire life cycle of the products.
USFDA
EDQM
Australian TGA
Taiwan FDA
Chinese FDA
Partnership with Harman will not only enable customers to free their existing production capacities but will also allow them to expand their technical resources without increasing their overheads for new projects.
By concentrating resources with a single-source provider, our customers can minimize technical transfer of projects or products, thereby reducing unforeseen costs and potentially speeding new products to market.
Customers can manage their internal resources and costs by focusing on core competencies and high-value projects while reducing or not adding infrastructure or technical staff.
Working with Harman will also limit our customers upfront capital investment for drug development, thus minimizing a project’s cost.